Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

Clinical Cardiology

Volumn 39, Issue 6, 2016, Pages 345-346

  Plitt, Anna ^a   Ezekowitz, Michael D ^b   De Caterina, Raffaele ^c   Nordio, Francesco ^d   Peterson, Nancy ^e   Giugliano, Robert P ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF CHIETI   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDOXABAN; WARFARIN;

AGE DISTRIBUTION; AGED; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; NOTE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84976321948     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22537     Document Type: Note

References (4)

1. Dentali F, Botto GL, Gianni M, et al. Efficacy and safety of direct oral anticoagulants in patients undergoing cardioversion for atrial fibrillation: a systematic review and meta-analysis of the literature. Int J Cardiol. 2015;185:72–77.
2. Cappato R, Ezekowitz MD, Klein AL, et al; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346–3355.
3. Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
4. Lip GY, Merino J, Ezekowitz M, et al. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) study. Am Heart J. 2015;169:597.e5–604.e5.